Table 4 One-year survival and one-year mortality rate ratio (MRR) by level of comorbidity according to the stage of cancer and adjusted for age and calendar time.
From: The impact of comorbidity and stage on ovarian cancer mortality: A nationwide Danish cohort study
Charlson Comorbidity score | |||
|---|---|---|---|
0 | 1–2 | 3+ | |
Localized tumour/FIGO-stage I | |||
Number | 774 | 184 | 37 |
Median age, years | 56 | 67 | 72 |
Survival in % | 95 (93–97) | 88 (82–92) | 81 (64–91) |
Crude MRR | 1 (ref.) | 2.8 (1.6–4.6) | 4.5 (2.0–10.0) |
Adj. MRR | 1 (ref.) | 2.1 (1.2–3.5) | 2.7 (1.2–6.2) |
Regional spread/FIGO-stage II, III | |||
Number | 1,757 | 492 | 157 |
Median age, years | 62 | 68 | 69 |
Survival in % | 77 (75–79) | 63 (59–67) | 47 (39–54) |
Crude MRR | 5.3 (3.8–7.4) | 9.2 (6.5–13.2) | 16.0 (10.9–23.6) |
Adj. MRR | 4.8 (3.5–6.8) | 7.1 (5.0–10.1) | 12.3 (8.3–18.1) |
Distant metastases/FIGO-stage IV | |||
Number | 1,002 | 338 | 140 |
Median age, years | 66 | 71 | 71 |
Survival in % | 50 (47–53) | 38 (33–44) | 34 (27–42) |
Crude MRR | 14.1 (10.1–19.7) | 20.4 (14.4–28.9) | 23.4 (16.0–34.2) |
Adj. MRR | 11.6 (8.3–16.2) | 13.9 (9.8–19.8) | 15.7 (10.7–23.1) |
Unspecified | |||
Number | 194 | 102 | 36 |
Median age, years | 66 | 75 | 71 |
Survival in % | 62 (55–68) | 40 (31–50) | 33 (19–49) |
Crude MRR | 10.1 (6.8–15.0) | 19.2 (12.8–28.9) | 25.0 (15.0–41.8) |
Adj. MRR | 8.1 (5.5–12.1) | 11.2 (7.4–16.8) | 15.3 (9.1–25.7) |